BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23972671)

  • 1. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.
    Holt SK; Kolb S; Fu R; Horst R; Feng Z; Stanford JL
    Cancer Epidemiol; 2013 Oct; 37(5):666-70. PubMed ID: 23972671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring.
    Gilbert R; Metcalfe C; Fraser WD; Lewis S; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM; Tilling K
    Eur J Cancer Prev; 2013 Mar; 22(2):121-5. PubMed ID: 22955340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
    Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer.
    Fang F; Kasperzyk JL; Shui I; Hendrickson W; Hollis BW; Fall K; Ma J; Gaziano JM; Stampfer MJ; Mucci LA; Giovannucci E
    PLoS One; 2011 Apr; 6(4):e18625. PubMed ID: 21494639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.
    Barnett CM; Nielson CM; Shannon J; Chan JM; Shikany JM; Bauer DC; Hoffman AR; Barrett-Connor E; Orwoll E; Beer TM
    Cancer Causes Control; 2010 Aug; 21(8):1297-303. PubMed ID: 20383574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association among plasma 1,25(OH)
    Ramakrishnan S; Steck SE; Arab L; Zhang H; Bensen JT; Fontham ETH; Johnson CS; Mohler JL; Smith GJ; Su LJ; Woloszynska A
    Prostate; 2019 Jul; 79(10):1117-1124. PubMed ID: 31077420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.
    Travis RC; Perez-Cornago A; Appleby PN; Albanes D; Joshu CE; Lutsey PL; Mondul AM; Platz EA; Weinstein SJ; Layne TM; Helzlsouer KJ; Visvanathan K; Palli D; Peeters PH; Bueno-de-Mesquita B; Trichopoulou A; Gunter MJ; Tsilidis KK; Sánchez MJ; Olsen A; Brenner H; Schöttker B; Perna L; Holleczek B; Knekt P; Rissanen H; Yeap BB; Flicker L; Almeida OP; Wong YYE; Chan JM; Giovannucci EL; Stampfer MJ; Ursin G; Gislefoss RE; Bjørge T; Meyer HE; Blomhoff R; Tsugane S; Sawada N; English DR; Eyles DW; Heath AK; Williamson EJ; Manjer J; Malm J; Almquist M; Marchand LL; Haiman CA; Wilkens LR; Schenk JM; Tangen CM; Black A; Cook MB; Huang WY; Ziegler RG; Martin RM; Hamdy FC; Donovan JL; Neal DE; Touvier M; Hercberg S; Galan P; Deschasaux M; Key TJ; Allen NE
    Cancer Res; 2019 Jan; 79(1):274-285. PubMed ID: 30425058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer.
    Wong YY; Hyde Z; McCaul KA; Yeap BB; Golledge J; Hankey GJ; Flicker L
    PLoS One; 2014; 9(6):e99954. PubMed ID: 24949795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade.
    Gilbert R; Metcalfe C; Fraser WD; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM
    Cancer Causes Control; 2012 Nov; 23(11):1865-73. PubMed ID: 22926301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
    Ahn J; Peters U; Albanes D; Purdue MP; Abnet CC; Chatterjee N; Horst RL; Hollis BW; Huang WY; Shikany JM; Hayes RB;
    J Natl Cancer Inst; 2008 Jun; 100(11):796-804. PubMed ID: 18505967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men.
    Meyer HE; Støer NC; Samuelsen SO; Blomhoff R; Robsahm TE; Brustad M; Giovannucci EL; Bjørge T
    PLoS One; 2016; 11(3):e0151441. PubMed ID: 26986958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    Shui IM; Mondul AM; Lindström S; Tsilidis KK; Travis RC; Gerke T; Albanes D; Mucci LA; Giovannucci E; Kraft P;
    Cancer; 2015 Jun; 121(12):1949-56. PubMed ID: 25731953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fok1 vitamin D receptor gene polymorphism and 25(OH) D serum levels and prostate cancer among Jordanian men.
    Atoum MF; AlKateeb D; AlHaj Mahmoud SA
    Asian Pac J Cancer Prev; 2015; 16(6):2227-30. PubMed ID: 25824742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk.
    Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M
    Br J Nutr; 2016 Jan; 115(2):305-14. PubMed ID: 26568368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.
    Mondul AM; Weinstein SJ; Moy KA; Männistö S; Albanes D
    Cancer Epidemiol Biomarkers Prev; 2016 Apr; 25(4):665-9. PubMed ID: 26809275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer.
    Webb PM; de Fazio A; Protani MM; Ibiebele TI; Nagle CM; Brand AH; Blomfield PI; Grant P; Perrin LC; Neale RE;
    Am J Clin Nutr; 2015 Jul; 102(1):109-14. PubMed ID: 25971716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer.
    Nair-Shalliker V; Bang A; Egger S; Clements M; Gardiner RA; Kricker A; Seibel MJ; Chambers SK; Kimlin MG; Armstrong BK; Smith DP
    Sci Rep; 2020 May; 10(1):7736. PubMed ID: 32385370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.